| Report Date | |
| Manager | |
| Fund Name | |
| Strategy | |
| Latest Return Date | |
| Latest Return | |
| Latest 6 Months | |
| Latest 12 Months | |
| Latest 24 Months (pa) | |
| Annualised Since Inception | |
| Inception Date | |
| FUM (millions) | |
| Fund Overview | |
| Manager Comments | The Fund's Sharpe and Sortino ratios (since inception), 1.07 and 1.50 respectively, by contrast with the Index's Sharpe of 0.47 and Sortino of 0.49, highlight its capacity to achieve superior risk-adjusted returns while avoiding the market's downside volatility. The Fund's ability to significantly outperform in both rising and falling markets is demonstrated by its up-capture and down-capture ratios (since inception) of 147.9% and 81.1% respectively. The portfolio's largest positive contributors in October came from long positions in ResMed Inc, AMP Ltd and Commonwealth Bank of Australia Ltd. The largest detractors were short positions in Challenger Ltd, Virgin Money UK and Cimic Ltd. The Fund ended the month with 32 long positions and 20 short position, with the largest exposure to medical devices & services and technology stocks. The Fund ended the month with relatively less exposure to banking and real estate stocks. |
| More Information |
